From Name:
From Email:
To Name:
To Email:

Optional Message:

FDA lowers nucleic-acid-based TB test risk classification

from Medscape Medical News

The risk classification for nucleic acid–based tests is being downgraded from class 3 (high risk) to class 2 (moderate risk) by the U.S. Food and Drug Administration (FDA), which will allow for easier approval of such tests. Class 3 device classification requires a more rigorous premarketing application and approval process. "This rule would lower the current risk classification for nucleic acid-based tests allowing manufacturers to utilize the faster, more streamlined clearance pathway for medical devices," according to the FDA. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063